Chris Degnan - 08 Oct 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
08 Oct 2024
Net transactions value
$0
Form type
4
Filing time
09 Oct 2024, 16:22:54 UTC
Previous filing
14 Mar 2023
Next filing
09 Oct 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +13,450 $0.000000 13,450 08 Oct 2024 Ordinary Shares 13,450 Direct F1, F2
transaction URGN Employee Stock Option (right to buy) Award $0 +74,142 $0.000000 74,142 08 Oct 2024 Ordinary Shares 74,142 $13.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.
F3 1/3 of the shares underlying the stock option will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.